# Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis

> **NCT00884585** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 176 (actual)

## Conditions studied

- Atopic Conjunctivitis

## Interventions

- **DRUG:** Cyclosporine Vehicle
- **DRUG:** Cyclosporine 0.010%

## Key facts

- **NCT ID:** NCT00884585
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2010-10
- **Final completion:** 2011-07
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2012-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00884585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00884585, "Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00884585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*